Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

BioFocus and Activiomics Announces Strategic Alliance

Published: Thursday, July 26, 2012
Last Updated: Wednesday, July 25, 2012
Bookmark and Share
BioFocus expands its drug discovery offering with proteomics technology from Activiomics.

BioFocus and Activiomics have announced a strategic alliance which will allow BioFocus to offer Activiomics’ proteomics services to its customers, to improve identification of novel targets for drug discovery and biomarkers for diagnostics.

Activiomics’ proprietary technology, TIQUAS (Targeted In-depth QUAntification of cell Signaling), provides valuable insights into which proteins or pathways have been activated following a cell signaling event, information that is generally not accessible using conventional expression analysis.

This has application in a range of therapeutic areas including oncology, inflammation and metabolic disease.

TIQUAS makes use of sophisticated mass spectroscopy-based techniques to detect and quantify thousands of phosphorylation sites from a cell/tissue extract.

This provides clues as to which proteins or pathways are activated, since change in phosphorylation status is indicative of a change in protein activity.

The output from this platform is analyzed using a range of proprietary bioinformatics tools.

Chris Newton, SVP Galapagos Services and MD BioFocus, commented: “Proteomics analysis, in particular phosphoproteomics, is becoming ever more important in drug discovery programs. By partnering with Activiomics, BioFocus extends its offering of high-quality scientific expertise into this newly emerging area.”

Mark Warne, Chief Executive Officer of Activiomics, added: “We are delighted to begin this strategic partnership with BioFocus. BioFocus is renowned for its fast, accurate and professional contract research service, making it an obvious choice of partner for Activiomics. We are looking forward to making our popular platform even more widely available through exposure to BioFocus’ large and growing client base.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Under the terms of the agreement, BioFocus will apply its drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Thursday, November 21, 2013
BioFocus Signs Agreement with Biogen Idec
The 3-year collaboration will focus on the identification and validation of novel targets in scleroderma.
Tuesday, November 12, 2013
BioFocus Signs Agreement with Aviva Investors
Pre-let agreement for construction of new laboratory and HQ building at Chesterford Research Park.
Thursday, September 05, 2013
BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
Grant will support the development of a novel Parkinson’s disease cell model.
Tuesday, June 25, 2013
BioFocus Launches Academic Engagement Initiative
Aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups.
Wednesday, May 01, 2013
BioFocus Extends its Collaboration with The Michael J. Fox Foundation
BioFocus has extended its collaboration agreement for Parkinson’s Research.
Thursday, April 18, 2013
Peter Rehse joins BioFocus as Senior Director, Structural Biology
BioFocus today announced that Dr. Peter Rehse has joined the company and will be based at Chesterford Park, near Cambridge, UK.
Monday, February 11, 2013
BioFocus Announces Agreement with ChanTest
BioFocus expands ion channel offering.
Thursday, February 07, 2013
BioFocus Achieves Milestone in its Drug Discovery Collaboration with UCB
Discovery milestone triggers payment from UCB and demonstrates BioFocus’ ability to support its clients.
Tuesday, December 04, 2012
BioFocus and Ono Sign a Drug Discovery Agreement
The collaboration agreement between Galapagos NV’s service division, BioFocus, and Ono Pharmaceutical Co., Ltd. will focus on discovering novel drugs in the field of CNS disorders.
Monday, September 03, 2012
BioFocus and Argenta Announce Drug Discovery Collaboration
Collaboration with AstraZeneca in respiratory and inflammatory disease.
Thursday, March 15, 2012
Almirall and BioFocus enter Research Alliance
Three-year integrated drug discovery alliance aims to identify drug development candidates for treating respiratory disease.
Wednesday, January 25, 2012
Argenta and BioFocus Announce Two-Year Extension Of Drug Discovery Collaboration with Genentech
Total potential value of the contract extension is up to £21.5 million (€23.4 million).
Monday, August 22, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
The collaboration will offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries.
Wednesday, August 03, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Microbe Sleuth
Tanja Bosak examines how life and the Earth evolved in tandem during their early history together.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Restoring Vision with Stem Cells
Age-related macular degeneration (AMRD) could be treated by transplanting photoreceptors produced by the directed differentiation of stem cells, thanks to findings published today by Professor Gilbert Bernier of the University of Montreal and its affiliated Maisonneuve-Rosemont Hospital.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos